索磷布韦维帕他韦片联合利巴韦林治疗慢性丙型病毒性肝炎的临床疗效研究

Clinical efficacy of sofosbuvir and velpatasvir tablets combined with ribavirin in the treatment of chronic viral hepatitis C

目的:探究索磷布韦维帕他韦片联合利巴韦林治疗慢性丙型病毒性肝炎的临床疗效。方法:选取2016年5月~2018年5月间在我院治疗的慢性丙型病毒性肝炎患者156例为研究对象,随机分为观察组和对照组,每组各78例。观察组78例采用索磷布韦维帕他韦片联合利巴韦林治疗,对照组78例采用利巴韦林治疗。治疗结束后以观察组与对照组患者的临床疗效,生活质量,肝功能,HCV-RNA水平,病毒学转阴率,不良反应发生率为评价指标。结果:观察组的治疗临床总有效率为97.44%明显高于对照组的71.79%,差异具统计学意义。观察组总体健康评分(80.27±10.05)比对照组(62.14±9.83)高,差异明显。治疗后观察组肝功能指标ALT、AST、TBIL的减少幅度及ALB的增加幅度均比对照组明显高,治疗后观察组HCV-RNA水平下降幅度比对照组明显大,差异显著。观察组治疗后RVR、EVR、ETVR、SVR率均显著高于对照组,差异显著,具统计学意义。观察组不良反应发生率为2.56%显著低于对照组不良反应发生率28.21%,差异显著。结论:索磷布韦维帕他韦片联合利巴韦林治疗慢性丙型病毒性肝炎可显著提高临床疗效,改善生活质量及肝功能,降低HCV-RNA水平,提高病毒学应答率,降低不良反应发生率,安全性好,值得临床推广。

Objective To investigate the clinical efficacy of sofosbuvir and velpatasvir tablets combined with ribavirin in the treatment of chronic viral hepatitis C.Methods A total of 156 patients with chronic hepatitis C who were treated in our hospital from May 2016 to May 2018 were enrolled in the study.They were randomly divided into observation group and control group,with 78 cases in each group.Seventy-eight patients in the observation group were treated with sofosbuvir and velpatasvir tablets combined with ribavirin,and 78 patients in the control group were treated with ribavirin.After treatment,the clinical efficacy,quality of life,liver function,HCV-RNA level,virological conversion rate,and incidence of adverse reactions were evaluated in the observation group and the control group.Results The total effective rate of treatment in the observation group was 97.44%,which was significantly higher than that in the control group(71.79%).The difference was statistically significant.The overall health score of the observation group(80.27±10.05)was higher than that of the control group(62.14±9.83),and the difference was significant.After treatment,the reduction of ALT,AST,TBIL and the increase of ALB in the observation group were significantly higher than those in the control group.The decrease of HCV-RNA level in the observation group was significantly larger than that in the control group,and the difference was significant.The RVR,EVR,ETVR,and SVR rates in the observation group were significantly higher than those in the control group,and the difference was statistically significant.The incidence of adverse reactions in the observation group was significantly higher than the incidence of adverse reactions in the control group by 28.21%,and the difference was significant.Conclusion Sofosbuvir and velpatasvir tablets with ribavirin in the treatment of chronic hepatitis C can significantly improve clinical efficacy,improve quality of life and liver function,reduce HCV-RNA levels,increase virological response rate,and reduce adverse reactions.Incidence,safety,and worthy of clinical promotion.